001     179436
005     20240229145544.0
024 7 _ |a 10.1158/1055-9965.EPI-21-0996
|2 doi
024 7 _ |a pmid:35086823
|2 pmid
024 7 _ |a 1055-9965
|2 ISSN
024 7 _ |a 1538-7755
|2 ISSN
024 7 _ |a altmetric:121706954
|2 altmetric
037 _ _ |a DKFZ-2022-00676
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Harbs, Justin
|b 0
245 _ _ |a Circulating Sex Hormone Levels and Colon Cancer Risk in Men: A Nested Case-Control Study and Meta-Analysis.
260 _ _ |a Philadelphia, Pa.
|c 2022
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1649333535_32468
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Endogenous sex hormones may contribute to higher colorectal cancer incidence rates in men compared with women, but despite an increased number of studies, clear evidence is lacking.We conducted a comprehensive nested case-control study of circulating concentrations of sex hormones, sex hormone precursors, and sex hormone binding globulin (SHBG) in relation to subsequent colon cancer risk in European men. Concentrations were measured using liquid LC/MS-MS in prospectively collected plasma samples from 690 cases and 690 matched controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS) cohorts. Multivariable conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). In addition, we conducted a meta-analysis of previous studies on men.Circulating levels of testosterone (OR, 0.68; 95% CI, 0.51-0.89) and SHBG (OR, 0.77; 95% CI, 0.62-0.96) were inversely associated with colon cancer risk. For free testosterone, there was a nonsignificant inverse association (OR, 0.83; 95% CI, 0.58-1.18). In a dose-response meta-analysis of endogenous sex hormone levels, inverse associations with colorectal/colon cancer risk were found for testosterone [relative risks (RR) per 100 ng/dL = 0.98; 95% CI, 0.96-1.00; I2 = 22%] and free testosterone (RR per 1 ng/dL = 0.98; 95% CI, 0.95-1.00; I2 = 0%).Our results provide suggestive evidence for the association between testosterone, SHBG, and male colon cancer development.Additional support for the involvement of sex hormones in male colon cancer.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Gonadal Steroid Hormones
|2 NLM Chemicals
650 _ 7 |a Sex Hormone-Binding Globulin
|2 NLM Chemicals
650 _ 7 |a Testosterone
|0 3XMK78S47O
|2 NLM Chemicals
650 _ 7 |a Estradiol
|0 4TI98Z838E
|2 NLM Chemicals
650 _ 2 |a Case-Control Studies
|2 MeSH
650 _ 2 |a Colonic Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Estradiol
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Gonadal Steroid Hormones
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Logistic Models
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Sex Hormone-Binding Globulin: metabolism
|2 MeSH
650 _ 2 |a Testosterone
|2 MeSH
700 1 _ |a Rinaldi, Sabina
|b 1
700 1 _ |a Gicquiau, Audrey
|b 2
700 1 _ |a Keski-Rahkonen, Pekka
|b 3
700 1 _ |a Mori, Nagisa
|b 4
700 1 _ |a Liu, Xijia
|b 5
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 6
|u dkfz
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 7
|u dkfz
700 1 _ |a Schulze, Matthias B
|0 0000-0002-0830-5277
|b 8
700 1 _ |a Agnoli, Claudia
|0 0000-0003-4472-1179
|b 9
700 1 _ |a Tumino, Rosario
|0 0000-0003-2666-414X
|b 10
700 1 _ |a Bueno-de-Mesquita, Bas
|b 11
700 1 _ |a Crous-Bou, Marta
|b 12
700 1 _ |a Sánchez, Maria-Jose
|0 0000-0003-4817-0757
|b 13
700 1 _ |a Aizpurua, Amaia
|b 14
700 1 _ |a Chirlaque, María-Dolores
|b 15
700 1 _ |a Gurrea, Aurelio Barricarte
|b 16
700 1 _ |a Travis, Ruth C
|0 0000-0002-9571-0763
|b 17
700 1 _ |a Watts, Eleanor L
|0 0000-0001-9229-2589
|b 18
700 1 _ |a Christakoudi, Sofia
|b 19
700 1 _ |a Tsilidis, Konstantinos K
|0 0000-0002-8452-8472
|b 20
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 21
700 1 _ |a Gunter, Marc J
|0 0000-0001-5472-6761
|b 22
700 1 _ |a Van Guelpen, Bethany
|0 0000-0002-9692-101X
|b 23
700 1 _ |a Murphy, Neil
|b 24
700 1 _ |a Harlid, Sophia
|0 0000-0001-8540-6891
|b 25
773 _ _ |a 10.1158/1055-9965.EPI-21-0996
|g Vol. 31, no. 4, p. 793 - 803
|0 PERI:(DE-600)2036781-8
|n 4
|p 793 - 803
|t Cancer epidemiology, biomarkers & prevention
|v 31
|y 2022
|x 1055-9965
909 C O |o oai:inrepo02.dkfz.de:179436
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER EPIDEM BIOMAR : 2021
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-10
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-10
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21